Loading organizations...
§ Private Profile · Le Kremlin-bicêtre, Ile-de-France, France
Biotechnology company developing enzymatic DNA synthesis technology for research and clinical labs, focused on on-demand synthetic DNA and RNA.
DNA Script has raised $475.0M across 6 funding rounds.
Key people at DNA Script.
DNA Script has raised $475.0M in total across 6 funding rounds.
Based in Paris, France, DNA Script is a biotechnology company that develops enzymatic DNA synthesis technology to enable the rapid, on-demand production of synthetic nucleic acids directly in laboratories. The firm's proprietary SYNTAX system functions as a benchtop DNA printer, replacing traditional chemical synthesis methods to accelerate genomics research, therapeutics development, and precision medicine. The enterprise has raised approximately $315 million in total venture funding to date, which includes a $200 million Series C round and an $89 million Series B financing. DNA Script is backed by prominent investors such as Casdin Capital, Sofinnova Partners, and Agilent Technologies, while collaborating with research institutions like the Broad Institute and Harvard University on a $23 million DNA data storage project. The biotechnology company was founded in 2014 by Thomas Ybert, Sylvain Gariel, and Xavier Godron.
Key people at DNA Script.
DNA Script has raised $475.0M across 6 funding rounds. Most recently, it raised $200.0M Series C in January 2022.
DNA Script is a pioneering life sciences technology company founded in 2014 that develops the world's first benchtop DNA printer powered by Enzymatic DNA Synthesis (EDS) technology.[1][2][3] Its flagship product, the SYNTAX System (including the STX-200 instrument), enables labs to produce high-quality, single-stranded DNA oligos up to 120 nt long—up to 96 at a time—in less than 24 hours, directly on-site.[4][6] DNA Script serves academic researchers, biopharma companies, and synthetic biology labs, solving the bottleneck of slow, outsourced chemical DNA synthesis by decentralizing rapid, on-demand production.[1][5][6] This accelerates workflows in therapeutics development, sustainable chemicals, crop improvement, and data storage, with over $315M raised from investors like Coatue, Fidelity, and Sofinnova Partners.[5]
The company's growth momentum includes broad commercial availability of the fully automated SYNTAX platform announced in 2023, partnerships with DARPA, Moderna, Illumina, and Institut Pasteur, and expansion from Paris headquarters to South San Francisco for commercialization.[4][5]
DNA Script was co-founded in 2014 in Paris, France, by Thomas Ybert, a physicist who at age 30 envisioned synthetic DNA as "the next silicon" due to its potential in storing digital data and driving biological innovation.[3][5] Ybert's idea emerged from recognizing limitations in traditional chemical (phosphoramidite) synthesis—slow turnaround, high costs, and poor scalability—and pivoting to proprietary template-free enzymatic technology developed over nearly three years in partnership with Institut Pasteur and Institut Pierre Gilles de Gennes.[1][3] Backed early by investors like Sofinnova Partners, Kurma Partners, and Idinvest (now part of Eurazeo), the company achieved pivotal traction through its SYNTAX early access program, leading to full commercialization and global expansion.[3][5]
DNA Script rides the synthetic biology boom, where decentralized DNA production fuels faster design-build-test-learn cycles in genomics, biopharma, and data storage—trends amplified by CRISPR advances and AI-driven protein design.[1][3][5] Timing is ideal amid post-pandemic demand for agile biotech tools, with market forces like supply chain vulnerabilities favoring on-site synthesis over centralized chemical providers.[6] By enabling full plasmids, artificial chromosomes, and synthetic genomes (e.g., yeast projects), DNA Script influences the ecosystem, empowering labs to innovate in therapeutics, sustainable agchem, and molecular data archiving, positioning DNA as a versatile "next silicon."[3][7]
DNA Script is poised to dominate EDS with SYNTAX expansions into longer oligos, full gene synthesis, and AI-optimized workflows, potentially capturing a slice of the $2B+ oligo market.[4][7] Rising synbio investment and regulatory tailwinds for green biotech will shape its path, evolving its influence from research enabler to industrial manufacturing standard—accelerating breakthroughs where DNA printing unlocks biology's full potential, just as promised in its benchtop revolution.[1][5]
DNA Script has raised $475.0M in total across 6 funding rounds.
DNA Script's investors include Catalio Capital, Presight Capital, Casdin Capital, Aaron Weiner, Rodolphe BESSERVE, Fidelity Management & Research Company, HealthCor, Irving Investors, T. Rowe Price Associates, 5AM Ventures, Abingworth, Alven.
